Valent Amy M, DeArmond Chris, Houston Judy M, Reddy Srinidhi, Masters Heather R, Gold Alison, Boldt Michael, DeFranco Emily, Evans Arthur T, Warshak Carri R
Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland.
Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, Ohio.
JAMA. 2017 Sep 19;318(11):1026-1034. doi: 10.1001/jama.2017.10567.
The rate of obesity among US women has been increasing, and obesity is associated with increased risk of surgical site infection (SSI) following cesarean delivery. The optimal perioperative antibiotic prophylactic regimen in this high-risk population undergoing cesarean delivery is unknown.
To determine rates of SSI among obese women who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery for the prevention of SSI in obese women (prepregnancy BMI ≥30) who had received standard intravenous preoperative cephalosporin prophylaxis. Randomization was stratified by intact vs rupture of membranes prior to delivery. The study was conducted at the University of Cincinnati Medical Center, Cincinnati, Ohio, an academic and urban setting, between October 2010 and December 2015, with final follow-up through February 2016.
Participants were randomly assigned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identical-appearing placebo (n = 201 participants) every 8 hours for a total of 48 hours following cesarean delivery.
The primary outcome was SSI, defined as any superficial incisional, deep incisional, or organ/space infections within 30 days after cesarean delivery.
Among 403 randomized participants who were included (mean age, 28 [SD, 6] years; mean BMI, 39.7 [SD, 7.8]), 382 (94.6%) completed the trial. The overall rate of SSI was 10.9% (95% CI, 7.9%-14.0%). Surgical site infection was diagnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo group (difference, 9.0% [95% CI, 2.9%-15.0%]; relative risk, 0.41 [95% CI, 0.22-0.77]; P = .01). There were no serious adverse events, including allergic reaction, reported in either the antibiotic group or the placebo group.
Among obese women undergoing cesarean delivery who received the standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate of SSI within 30 days after delivery. For prevention of SSI among obese women after cesarean delivery, prophylactic oral cephalexin and metronidazole may be warranted.
clinicaltrials.gov Identifier: NCT01194115.
美国女性肥胖率一直在上升,且肥胖与剖宫产术后手术部位感染(SSI)风险增加相关。在这一接受剖宫产的高危人群中,最佳围手术期抗生素预防方案尚不清楚。
确定剖宫产术后接受预防性口服头孢氨苄和甲硝唑48小时的肥胖女性与接受安慰剂的肥胖女性的SSI发生率。
设计、设置和参与者:一项随机、双盲临床试验,比较剖宫产术后口服头孢氨苄和甲硝唑与安慰剂48小时对肥胖女性(孕前BMI≥30)SSI的预防效果,这些女性术前已接受标准静脉注射头孢菌素预防。随机分组按分娩前胎膜完整与否进行分层。该研究于2010年10月至2015年12月在俄亥俄州辛辛那提市的辛辛那提大学医学中心进行,这是一个学术性的城市环境,最终随访至2016年2月。
参与者被随机分配接受口服头孢氨苄500mg和甲硝唑500mg(n = 202名参与者),与外观相同的安慰剂(n = 201名参与者),剖宫产术后每8小时一次,共48小时。
主要结局为SSI,定义为剖宫产术后30天内任何浅表切口、深部切口或器官/腔隙感染。
在纳入的403名随机参与者中(平均年龄28[标准差,6]岁;平均BMI 39.7[标准差,7.8]),382名(94.6%)完成了试验。SSI总发生率为10.9%(95%CI,7.9%-14.0%)。头孢氨苄-甲硝唑组13名女性(6.4%)被诊断为手术部位感染,而安慰剂组为31名女性(15.4%)(差异为9.0%[95%CI,2.9%-15.0%];相对风险为0.41[95%CI,0.22-0.77];P = 0.01)。抗生素组和安慰剂组均未报告包括过敏反应在内的严重不良事件。
在接受标准术前头孢菌素预防的剖宫产肥胖女性中,与安慰剂相比,术后口服头孢氨苄和甲硝唑48小时可降低分娩后30天内的SSI发生率。对于预防剖宫产术后肥胖女性的SSI,预防性口服头孢氨苄和甲硝唑可能是必要的。
clinicaltrials.gov标识符:NCT01194115。